This is a clinical practice guideline for patients with cancer of the uterine cervix, including those with squamous cell carcinomas, adenocarcinomas and adenosquamous carcinomas. The guideline examines screening, diagnosis, staging, treatment, and follow-up of these patients. Specific topics discussed include investigations of abnormal pap smears, investigations for staging, estrogen replacement therapy, and much more. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline for asymptomatic women with suspected or confirmed adnexal masses. The guideline provides recommendations on various imaging procedures used to confirm the presence of adnexal masses, and to determine whether they are benign or malignant. The appropriateness of procedures indicated in specific clinical scenarios (measured by validity, reliability/reproducibility, clinical applicability, relative radiation levels, etc.) is examined. Recommendations are separated based on menopausal status.

This is a clinical practice guideline on cervical cancer screening. This guideline provides recommendations regarding screening intervals, the appropriate management of screen-detected abnormalities, screening in specific populations and abnormal vaginal bleeding. Outcomes of interest include cervical cancer mortality, cervical cancer diagnosis and precancerous high grade lesion detection. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of August 30th, 2019.

This is a clinical practice guideline for women with cervical intraepithelial neoplasia (CIN). Recommendations are provided on the use of thermal ablation for the treatment of these women, with the ultimate goal of reducing the incidence of cervical cancer. The guideline compares thermal ablation to other treatment approaches such as cryotherapy, large loop excision of the transformation zone (LLETZ), and cold knife conization (CKC). Different modalities of thermal ablation (e.g., those that differ by temperature, number of applications, duration, etc.) are also discussed.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline on the screening for cervical cancer. The guideline examines the age at which to begin and end screening, the optimal interval for screening, the effectiveness of different screening strategies, and related benefits and harms of different screening strategies. Specific strategies discussed include screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years, screening every 3 years with cervical cytology alone, screening every 5 years with high-risk human papillomavirus (HPV) testing alone, and screening every 5 years with high-risk HPV testing in combination with cytology (co-testing) in women aged 30 to 65 years.

This is a clinical practice guideline for patients with cervical cancer. The guideline examines the staging, management, and follow-up of these patients. Specific management recommendations are made for stage T1a, T1b1/T2a1 cancer, clinically occult cervical cancer diagnosed after simple hysterectomy, early and locally advanced cervical cancer (LACC), primary distant metastatic disease, cervical cancer in pregnancy (CCIP), and recurrent disease. The use of fertility sparing treatment (FST) is also discussed.

This is a clinical practice guideline for adult oncology patients with neutropenia. The guideline examines the appropriate prescribing of filgrastim for these patients. Indications for which filgrastim should be used are discussed by disease site group. Disease site groups considered include breast, central nervous system, gastrointestinal, gynecologic, genitourinary, hematologic, and thoracic, amongst others.

This is a clinical practice guideline for women with potentially curable, non-operable, locally advanced cervical cancer. The guideline provides recommendations on treatment using brachytherapy (BT), and compares different forms of BT such as two-dimensional BT, computed tomography-guided BT, magnetic resonance (MR)-guided intracavitary BT, and MR-guided intracavitary/interstitial BT. Outcomes of interest include survival, local tumour control, and toxicity.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline for patients with cervical cancer. The guideline discusses the diagnosis, treatment, and surveillance of patients with primary cervical cancer, and also provides recommendations regarding the treatment of recurrent cervical cancer. Specific diagnostic techniques examined include computed tomography (CT) and positron emission tomography (PET) scans, while treatment modalities examined include laparoscopic and robotic radical hysterectomy, nerve sparing radical hysterectomy, intensity-modulated radiation therapy (IMRT), and more.

This is a clinical practice guideline for the vaccination of human papillomavirus (HPV) for the prevention of cervical cancer in women. The guideline examines the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the cross-protective ability of each HPV preventive vaccine.

This is a clinical practice guideline for the use of myeloid growth factors in adult patients with solid tumours and non-myeloid malignancies. Benefits and risks are reviewed, the role of biosimilars is discussed, and recommendations are provided for prophylactic and therapeutic uses of both granulocyte and granulocyte-macrophage colony stimulating factors (CSFs). Recommendations are also given regarding the use of CSFs in the hematopoietic cell transplant setting. Outcomes of interest include efficacy of CSFs, mortality, length of hospitalization, toxicity, and adverse effects.

This is a clinical practice guideline for females and males between the ages of 9 and 26. The guideline examines the use of the human papillomavirus (HPV) vaccination for the purposes of cancer prevention. The ages at which routine vaccination and catch-up vaccination should occur are discussed, as well as which vaccines should be used for males and females. Special populations such as men who have sex with other men and immunocompromised persons are also addressed.

This is a clinical practice guideline for palliative oncology patients 18 years of age or older with low grade/ low volume/ malignancy-associated urogenital or gastrointestinal bleeding, or with malignant gastrointestinal obstruction, compression or invasion. External beam radiotherapy (EBRT) with or without , brachytherapy, stent placement, and surgical bypass are discussed as therapeutic options. Outcomes of interest include clinical improvement of symptoms, quality of life, and survival.

This is a clinical practice guideline for women who are at risk of developing cervical cancer. The guideline examines the optimal methods for cervical cancer screening and the management of women with abnormal screening results. Primary screening, exiting screening, triage and post-triage time periods, and the treatment of women with precursor lesions are all discussed. Different recommendations are provided based on economic resource level (i.e., basic, limited, enhanced or maximal).

This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.

This guideline outlines the screening, diagnosis, treatment, and follow-up of human papillomavirus related cancers. The guideline examines appropriate vaccination strategies, screening (including care controversies), and treatment including chemotherapy and surgical options. Outcomes of interest include fertility sparing and reduction of unnecessary Pap testing. Provincial resources are provided.

This is a clinical practice guideline for women diagnosed with invasive cervical cancer. The guideline examines the most effective antitumour and palliative care interventions for clinicians and planners. Treatment options that are discussed include cone biopsy, extrafascial hysterectomy, modified radical or radical hysterectomy, and combinations of surgery, chemotherapy, and radiation therapy.

This is a clinical practice guideline for the screening and treatment of precancerous lesions for cervical cancer prevention. The guideline focuses specifically on the screening for cervical intraepithelial neoplasia 2 & 3 and the treatment of those lesions to prevent cervical cancer in women who tested positive after screening. In formulating the recommendations, the guideline authors specifically took into account resource implications in the Saudi context.

This clinical practice guideline examines the impact of fertility drugs on the risk of cancer in women. The guideline looks at the association between use of fertility drugs and increased risk of developing invasive ovarian, breast, endometrial, colon and thyroid cancers as well as non-Hodgkin lymphoma and malignant melanoma. The association between fertility drugs and borderline ovarian tumours is also examined.

A clinical practice guideline for female patients who have received potentially curative primary treatment for cervical cancer. The guideline examines appropriate follow-up strategies including minimum levels of screening and follow-up intervals. Outcomes of interest include recurrences detected during screening and survival rates.

A clinical practice guideline for the management of female patients with cervical cancer. The guideline examines diagnosis, staging, treatment including surgery and adjuvant therapy, and follow up. Outcomes of interest include fertility preservations and improved quality of life through hormonal replacement therapy during follow up.

This guideline outlines the screening, diagnosis, treatment, and follow-up of human papillomavirus related cancers. The guideline examines appropriate vaccination strategies, screening (including care controversies), and treatment including chemotherapy and surgical options. Outcomes of interest include fertility sparing and reduction of unnecessary Pap testing.

An organizational guideline for the provision of colonoscopies to patients with abnormal cervical screening results. The guideline examines the provision of consistent quality in colonoscopies, including training and competence, practices, and quality indicators. Important aspects include training program availability, referral criteria, and group vs. individual practice requirements.

A clinical practice guideline for treatment of uterine cervical cancer. The guideline examines updated evidence on primary treatments, treatment for recurrent cancers, and additional presentations, focusing primarily of lymphadenectomy and hysterectomy. Outcomes of interest include recurrence and fertility preservation.

This guideline provides recommendations on the use of advanced practice nurses (APNs) to optimize patient, provider, and health system outcomes across the cancer care continuum. Specifically, the guideline reviews patient populations and situations (types of needs, practice settings, phase of the cancer care continuum) for which APN roles have demonstrated equivalent or improved outcomes, or reduced harms in cancer care. Outcomes of interest include quality of life, physical, functional, psychosocial, and mental health, as well as morbidity, mortality, symptom management, patient and provider satisfaction, health care utilization, costs, and quality of care.

This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.

This is a clinical practice guideline for cervical cancer screening for asymptomatic women aged over 20. The guideline committee considered the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papillomavirus (HPV) testing. Other areas of interest addressed in this guideline include: the age to begin and the age to terminate and screening interval; as well as the false-positive and resulting the psychological harms in screening.

This is a clinical practice guideline for patients with invasive cancer of the cervix. The guideline addresses staging techniques using imaging. This includes a review of the use of radiographs, excretory urography, transabdominal ultrasound (TRUS), computed tomography (CT), magnetic resonance imaging (MRI), lymphangiography and lymphoscintigraphy, positron emission tomography (PET) and PET/computed tomography, and nuclear medicine bone scan. Trachelectomy assessment is also discussed.

A clinical practice guideline for the management of adult patients with cancer of the uterine cervix, including squamous, adenocarcinomas, and adenosquamous carcinomas. The guideline examines treatment, primarily through surgery and radiotherapy, staging, and follow-up. Outcomes of interest include improved survival benefits through chemoradiotherapy and improved outcomes thought the addition of ifosamide to recommended chemotherapies.

This guideline reviews the use of gynecological surgery for hysterectomy and myomectomy. Specific topics include morcellation techniques, diagnosis of uterine malignancy, and prognosis following surgery for uterine sarcomas. Complications with uterine morcellation are also discussed. Outcomes of interest include 5-year survival, abdominopelvic recurrence, and rate of complications.

This is a clinical practice guideline for patients of all age groups suspected of having cancers including lung and pleural, upper gastro-intestinal, lower gastrointestinal, breast, gynecological, urological, skin, head and neck, brain and central nervous system, haematological, sarcomas, and childhood cancers. Recommendations are provided on recognition and referral or investigations of cancer in primary care. Outcomes of interest include quality of life, sensitivity and specificity of diagnostic tests and signs/symptoms, positive and negative predictive values of diagnostic tests and signs/symptoms, and cost effectiveness.